Oncopeptides
Latest round
- Series A
Last raised
- May 2013
Total raised
- Undisclosed
Investors
- 2
About Oncopeptides
Founded in 2000 and based in Stockholm, Sweden, Oncopeptides AB operates as a pharmaceutical company that develops anti-cancer drug research as treatments for cancer patients. The company offers anti-cancer drugs for cancer treatment such as "Melflufen", a cancer treatment for hematological cancers developed by Dr. Joachim Gullbo at Uppsala University collaborated with the Harvard Medical School and Dana Farber of Cancer Institute. Oncopeptides AB's revenue is generated from developing drugs specifically for cancer patients.
Who invested in Oncopeptides
2 investors across 1 round
See all investors in Oncopeptides
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
May 21, 2013
Amount
Undisclosed
Investors
Questions about Oncopeptides
Who invested in Oncopeptides?
Oncopeptides has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Oncopeptides raised?
Oncopeptides has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Oncopeptides last raise money?
Oncopeptides's most recent round on record is a Series A, in May 2013.
What does Oncopeptides do?
Founded in 2000 and based in Stockholm, Sweden, Oncopeptides AB operates as a pharmaceutical company that develops anti-cancer drug research as treatments for cancer patients.
Where is Oncopeptides headquartered?
Oncopeptides is headquartered in Stockholm, Sweden.
Which VCs invest in companies like Oncopeptides?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back pharmaceuticals companies at Oncopeptides's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like Oncopeptides? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.